John T Stoffel1, Andrew C Peterson2, Jaspreet S Sandhu3, Anne M Suskind4, John T Wei5, Deborah J Lightner6. 1. University of Michigan, Ann Arbor, Michigan. Electronic address: jstoffel@med.umich.edu. 2. Duke University, Durham, North Carolina. 3. Memorial Sloan Kettering Hospital, New York, New York. 4. University of Calfornia, San Francisco, San Francisco, California. 5. University of Michigan, Ann Arbor, Michigan. 6. Mayo Clinic, Rochester, Minnesota.
Abstract
PURPOSE: The AUA (American Urological Association) QIPS (Quality Improvement and Patient Safety) committee created a white paper on the diagnosis and management of nonneurogenic chronic urinary retention. MATERIALS AND METHODS: Recommendations for the white paper were based on a review of the literature and consensus expert opinion from the workgroup. RESULTS: The workgroup defined nonneurogenic chronic urinary retention as an elevated post-void residual of greater than 300 mL that persisted for at least 6 months and documented on 2 or more separate occasions. It is proposed that chronic urinary retention should be categorized by risk (high vs low) and symptomatology (symptomatic versus asymptomatic). High risk chronic urinary retention was defined as hydronephrosis on imaging, stage 3 chronic kidney disease or recurrent culture proven urinary tract infection or urosepsis. Symptomatic chronic urinary retention was defined as subjectively moderate to severe urinary symptoms impacting quality of life and/or a recent history of catheterization. A treatment algorithm was developed predicated on stratifying patients with chronic urinary retention first by risk and then by symptoms. The proposed 4 primary outcomes that should be assessed to determine effectiveness of retention treatment are 1) symptom improvement, 2) risk reduction, 3) successful trial of voiding without catheterization, and 4) stability of symptoms and risk over time. CONCLUSIONS: Defining and categorizing nonneurogenic chronic urinary retention, creating a treatment algorithm and proposing treatment end points will hopefully spur comparative research that will ultimately lead to a better understanding of this challenging condition.
PURPOSE: The AUA (American Urological Association) QIPS (Quality Improvement and Patient Safety) committee created a white paper on the diagnosis and management of nonneurogenic chronic urinary retention. MATERIALS AND METHODS: Recommendations for the white paper were based on a review of the literature and consensus expert opinion from the workgroup. RESULTS: The workgroup defined nonneurogenic chronic urinary retention as an elevated post-void residual of greater than 300 mL that persisted for at least 6 months and documented on 2 or more separate occasions. It is proposed that chronic urinary retention should be categorized by risk (high vs low) and symptomatology (symptomatic versus asymptomatic). High risk chronic urinary retention was defined as hydronephrosis on imaging, stage 3 chronic kidney disease or recurrent culture proven urinary tract infection or urosepsis. Symptomatic chronic urinary retention was defined as subjectively moderate to severe urinary symptoms impacting quality of life and/or a recent history of catheterization. A treatment algorithm was developed predicated on stratifying patients with chronic urinary retention first by risk and then by symptoms. The proposed 4 primary outcomes that should be assessed to determine effectiveness of retention treatment are 1) symptom improvement, 2) risk reduction, 3) successful trial of voiding without catheterization, and 4) stability of symptoms and risk over time. CONCLUSIONS: Defining and categorizing nonneurogenic chronic urinary retention, creating a treatment algorithm and proposing treatment end points will hopefully spur comparative research that will ultimately lead to a better understanding of this challenging condition.
Authors: Jason Gilleran; Ananias C Diokno; Elijah Ward; Larry Sirls; Deborah Hasenau; Jennifer Giordano; Evelyn Shea; Sarah N Bartolone; Laura E Lamb; Michael B Chancellor Journal: Int Urol Nephrol Date: 2021-04-11 Impact factor: 2.370
Authors: Jerry L Lowder; Tamara G Bavendam; Amanda Berry; Sonya S Brady; Colleen M Fitzgerald; Cynthia S Fok; Patricia S Goode; Cora E Lewis; Elizabeth R Mueller; Diane K Newman; Mary H Palmer; Leslie Rickey; Ann Stapleton; Emily S Lukacz Journal: Neurourol Urodyn Date: 2019-04-08 Impact factor: 2.696
Authors: Andrew C Peterson; Abigail R Smith; Matthew O Fraser; Claire C Yang; John O L DeLancey; Brenda W Gillespie; John L Gore; Pooja Talaty; Victor P Andreev; Karl J Kreder; Margaret G Mueller; H Henry Lai; Bradley A Erickson; Ziya Kirkali Journal: Urology Date: 2019-04-21 Impact factor: 2.649
Authors: Imad Bentellis; Gérard Amarenco; Xavier Gamé; Dora Jericevic; Mehdi El-Akri; Caroline Voiry; Lucas Freton; Juliette Hascoet; Quentin Alimi; Jacques Kerdraon; Benjamin M Brucker; Benoit Peyronnet Journal: Clin Auton Res Date: 2019-08-26 Impact factor: 4.435